Literature DB >> 22236337

Hsp70 alters tau function and aggregation in an isoform specific manner.

Kellen Voss1, Benjamin Combs, Kristina R Patterson, Lester I Binder, T Chris Gamblin.   

Abstract

Tauopathies are characterized by abnormal aggregation of the microtubule associated protein tau. This aggregation is thought to occur when tau undergoes shifts from its native conformation to one that exposes hydrophobic areas on separate monomers, allowing contact and subsequent association into oligomers and filaments. Molecular chaperones normally function by binding to exposed hydrophobic stretches on proteins and assisting in their refolding. Chaperones of the heat shock protein 70 (Hsp70) family have been implicated in the prevention of abnormal tau aggregation in adult neurons. Tau exists as six alternatively spliced isoforms, and all six isoforms appear capable of forming the pathological aggregates seen in Alzheimer's disease. Because tau isoforms differ in primary sequence, we sought to determine whether Hsp70 would differentially affect the aggregation and microtubule assembly characteristics of the various tau isoforms. We found that Hsp70 inhibits tau aggregation directly and not through inducer-mediated effects. We also determined that Hsp70 inhibits the aggregation of each individual tau isoform and was more effective at inhibiting the three repeat isoforms. Finally, all tau isoforms robustly induced microtubule formation while in the presence of Hsp70. The results presented herein indicate that Hsp70 affects tau isoform dysfunction while having very little impact on the normal function of tau to mediate microtubule assembly. This indicates that targeting Hsp70 to tau may provide a therapeutic approach for the treatment of tauopathies that avoids disruption of normal tau function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236337      PMCID: PMC3278803          DOI: 10.1021/bi2018078

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  70 in total

Review 1.  Tau protein as a differential biomarker of tauopathies.

Authors:  Nicolas Sergeant; André Delacourte; Luc Buée
Journal:  Biochim Biophys Acta       Date:  2005-01-03

Review 2.  Tau splicing and the intricacies of dementia.

Authors:  Athena Andreadis
Journal:  J Cell Physiol       Date:  2012-03       Impact factor: 6.384

3.  Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.

Authors:  Kristina R Patterson; Christine Remmers; Yifan Fu; Sarah Brooker; Nicholas M Kanaan; Laurel Vana; Sarah Ward; Juan F Reyes; Keith Philibert; Marc J Glucksman; Lester I Binder
Journal:  J Biol Chem       Date:  2011-05-06       Impact factor: 5.157

4.  Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies.

Authors:  Yuri Umeda; Sayuri Taniguchi; Kunimasa Arima; Yue-Shan Piao; Hitoshi Takahashi; Takeshi Iwatsubo; David Mann; Masato Hasegawa
Journal:  Neurosci Lett       Date:  2004-04-15       Impact factor: 3.046

5.  Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study.

Authors:  G Lace; G M Savva; G Forster; R de Silva; C Brayne; F E Matthews; J J Barclay; L Dakin; P G Ince; S B Wharton
Journal:  Brain       Date:  2009-03-24       Impact factor: 13.501

6.  Molecular chaperone-mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain.

Authors:  N Sahara; S Maeda; Y Yoshiike; T Mizoroki; S Yamashita; M Murayama; J-M Park; Y Saito; S Murayama; A Takashima
Journal:  J Neurosci Res       Date:  2007-11-01       Impact factor: 4.164

7.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

8.  Quantitative analysis of tau isoform transcripts in sporadic tauopathies.

Authors:  J W Connell; T Rodriguez-Martin; G M Gibb; N M Kahn; A J Grierson; D P Hanger; T Revesz; P L Lantos; B H Anderton; J-M Gallo
Journal:  Brain Res Mol Brain Res       Date:  2005-03-29

9.  Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain.

Authors:  M Goedert; M G Spillantini; M C Potier; J Ulrich; R A Crowther
Journal:  EMBO J       Date:  1989-02       Impact factor: 11.598

Review 10.  Chaperone signalling complexes in Alzheimer's disease.

Authors:  John Koren; Umesh K Jinwal; Daniel C Lee; Jeffrey R Jones; Cody L Shults; Amelia G Johnson; Laura J Anderson; Chad A Dickey
Journal:  J Cell Mol Med       Date:  2009-04       Impact factor: 5.310

View more
  30 in total

1.  Tau protein aggregates inhibit the protein-folding and vesicular trafficking arms of the cellular proteostasis network.

Authors:  Anan Yu; Susan G Fox; Annalisa Cavallini; Caroline Kerridge; Michael J O'Neill; Joanna Wolak; Suchira Bose; Richard I Morimoto
Journal:  J Biol Chem       Date:  2019-04-01       Impact factor: 5.157

Review 2.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

Review 3.  Therapeutic Strategies for Restoring Tau Homeostasis.

Authors:  Zapporah T Young; Sue Ann Mok; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2018-01-02       Impact factor: 6.915

4.  Tau and neuron aging.

Authors:  Jesus Avila; Elena Gomez de Barreda; Noemi Pallas-Bazarra; Felix Hernandez
Journal:  Aging Dis       Date:  2012-12-03       Impact factor: 6.745

5.  Stabilizing the Hsp70-Tau Complex Promotes Turnover in Models of Tauopathy.

Authors:  Zapporah T Young; Jennifer N Rauch; Victoria A Assimon; Umesh K Jinwal; Misol Ahn; Xiaokai Li; Bryan M Dunyak; Atta Ahmad; George A Carlson; Sharan R Srinivasan; Erik R P Zuiderweg; Chad A Dickey; Jason E Gestwicki
Journal:  Cell Chem Biol       Date:  2016-08-04       Impact factor: 8.116

Review 6.  Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs).

Authors:  Francois-Xavier Theillet; Andres Binolfi; Tamara Frembgen-Kesner; Karan Hingorani; Mohona Sarkar; Ciara Kyne; Conggang Li; Peter B Crowley; Lila Gierasch; Gary J Pielak; Adrian H Elcock; Anne Gershenson; Philipp Selenko
Journal:  Chem Rev       Date:  2014-06-05       Impact factor: 60.622

Review 7.  Tau Protein Squired by Molecular Chaperones During Alzheimer's Disease.

Authors:  Nalini Vijay Gorantla; Subashchandrabose Chinnathambi
Journal:  J Mol Neurosci       Date:  2018-09-28       Impact factor: 3.444

Review 8.  Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door?

Authors:  Subhankar Paul; Sailendra Mahanta
Journal:  Mol Cell Biochem       Date:  2013-10-05       Impact factor: 3.396

Review 9.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

10.  Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels.

Authors:  Yoshinari Miyata; Xiaokai Li; Hsiu-Fang Lee; Umesh K Jinwal; Sharan R Srinivasan; Sandlin P Seguin; Zapporah T Young; Jeffrey L Brodsky; Chad A Dickey; Duxin Sun; Jason E Gestwicki
Journal:  ACS Chem Neurosci       Date:  2013-03-20       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.